Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
18.8
Year-on-year change in net sales (%)Wording
Conditional
How definitive the wording is.Contents of this document
Results presentationSecond quarter (cumulative) of the fiscal year ending March 202710 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥3,533 million+18.8%
Operating profit¥798 million+19.9%
Ordinary income¥830 million+22.8%
Net income¥578 million +2.1%interim net income attributable to owners of the parent
Operating profit margin
Rate22.6
Full-year earnings forecast
Net Sales
¥7,383 million
Operating profit
¥1,511 million
Ordinary income
¥1,520 million
Profit attributable to owners of the parent
¥1,056 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales47.9%
Operating profit52.8%
Ordinary income54.6%
Interim net income54.7%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progressing steadily against the full-year planAssumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- Expect to expand the Medical business's earnings base and receive performance contributions from subsidiaries acquired through M&A
- Includes depreciation of MightyChecker Cloud X and amortisation of goodwill and integration-related costs associated with M&A
- The earnings contribution from converting AI-driven development into production projects has been conservatively excluded from the earnings forecast
- No material impact from geopolitical risks, including the situation in the Middle East, is anticipated
New initiatives
- Making Radianceware Co., Ltd. a wholly owned subsidiary
- Strengthening strategic partnership collaboration with Kobelco Systems Corporation
- Launching MightyChecker Cloud X
- Building a 200-person AI-native engineering organisation
- Consolidating administrative functions across group companies and improving efficiency through the use of AI
Key KPIsA metric the company considers important as a management benchmark.
- Mighty series users (hospitals)3,963 facilities
- Mighty series users (clinics)19,490 facilities
- Mighty series share among hospitals50 Approximately %
- Mighty series share among clinics18 Approximately %
- Number of companies using the Insurance Knowledge Platform6 companies
- Number of companies with AI-related projects24 companies
- Number of industries represented by AI-related projects9 Industry
Segment results
Medical business
Net Sales
¥1,353 million+42.6%
Operating profit
¥659 million+9.5%
AI Technology Strategic business
Net Sales
¥2,180 million+7.6%
Operating profit
¥313 million+73.2%
Medium-term management plan targets
M&A
Target fiscal year2,030
Target valueCumulative total of 8–10 companies
Group direct-sales ratio
Current status4.8%
Target fiscal year2,030
Target value35%
LTV
Current status¥1.28 million
Target fiscal year2,030
Target value¥1.97 million (+54%)
CAC
Target fiscal year2,030
Target value15% reduction
LTV/CAC ratio
Current status9.3x
Target fiscal year2,030
Target value14.2x
Market Size / Share
- Domestic IT modernization services marketApproximately ¥1.3044 trillionFiscal year2,025
- Domestic IT modernization services marketApproximately ¥2.1234 trillionFiscal year2,030
- Mighty series share among hospitalsApproximately 50%
- Mighty series share among clinicsApproximately 18%
Number of employees
AI-native engineer
Operating70 People
Education60 People
Current fiscal-year target200 People
Annual Dividend
Fiscal year ending March 2027
Stable Dividends¥25 per share
Performance-Linked DividendsUndecided as of this date
Payout ratio
A guideline of 50% or more over the medium to long term| Item | Details |
|---|---|
| Document type | Results presentation |
| Fiscal Period Covered | Second quarter (cumulative) of the fiscal year ending March 2027 |
| Net Sales | ¥3,533 million (YoY +18.8%) |
| Operating profit | ¥798 million (YoY +19.9%) |
| Ordinary income | ¥830 million (YoY +22.8%) |
| Net income | ¥578 million (interim net income attributable to owners of the parent) (YoY +2.1%) |
| Operating profit margin | Rate 22.6 / Year-on-year change (points) Not disclosed |
| Full-year earnings forecast | Net Sales ¥7,383 million / Operating profit ¥1,511 million / Ordinary income ¥1,520 million / Profit attributable to owners of the parent ¥1,056 million |
| Progress against full-year forecast | Net Sales 47.9% / Operating profit 52.8% / Ordinary income 54.6% / Interim net income 54.7% |
| Self-assessment against the plan | Progressing steadily against the full-year plan |
| Segment results | Medical business Net Sales ¥1,353 million (YoY +42.6%) / Operating profit ¥659 million (YoY +9.5%) / AI Technology Strategic business Net Sales ¥2,180 million (YoY +7.6%) / Operating profit ¥313 million (YoY +73.2%) |
| Key KPIs | Indicator name Mighty series users (hospitals) / Value 3,963 facilities / Year on year against the same period last year Not disclosed, Indicator name Mighty series users (clinics) / Value 19,490 facilities / Year on year against the same period last year Not disclosed, Indicator name Mighty series share among hospitals / Value 50 Approximately % / Year on year against the same period last year Not disclosed, Indicator name Mighty series share among clinics / Value 18 Approximately % / Year on year against the same period last year Not disclosed, Indicator name Number of companies using the Insurance Knowledge Platform / Value 6 companies / Year on year against the same period last year Not disclosed, Indicator name Number of companies with AI-related projects / Value 24 companies / Year on year against the same period last year Not disclosed, Indicator name Number of industries represented by AI-related projects / Value 9 Industry / Year on year against the same period last year Not disclosed |
| Number of employees | AI-native engineer Operating 70 People / Education 60 People / Current fiscal-year target 200 People |
| Assumptions Underlying the Business Outlook | Expect to expand the Medical business's earnings base and receive performance contributions from subsidiaries acquired through M&A, Includes depreciation of MightyChecker Cloud X and amortisation of goodwill and integration-related costs associated with M&A, The earnings contribution from converting AI-driven development into production projects has been conservatively excluded from the earnings forecast, No material impact from geopolitical risks, including the situation in the Middle East, is anticipated |
| Medium-term management plan targets | M&A Target fiscal year 2,030 / Target value Cumulative total of 8–10 companies / Group direct-sales ratio Current status 4.8% / Target fiscal year 2,030 / Target value 35% / LTV Current status ¥1.28 million / Target fiscal year 2,030 / Target value ¥1.97 million (+54%) / CAC Target fiscal year 2,030 / Target value 15% reduction / LTV/CAC ratio Current status 9.3x / Target fiscal year 2,030 / Target value 14.2x |
| Annual Dividend | Fiscal year ending March 2027 Stable Dividends ¥25 per share / Performance-Linked Dividends Undecided as of this date |
| Payout ratio | A guideline of 50% or more over the medium to long term |
| Market Size / Share | Market Domestic IT modernization services market / Value Approximately ¥1.3044 trillion / Fiscal year 2,025, Market Domestic IT modernization services market / Value Approximately ¥2.1234 trillion / Fiscal year 2,030, Market Mighty series share among hospitals / Value Approximately 50%, Market Mighty series share among clinics / Value Approximately 18% |
| New initiatives | Making Radianceware Co., Ltd. a wholly owned subsidiary, Strengthening strategic partnership collaboration with Kobelco Systems Corporation, Launching MightyChecker Cloud X, Building a 200-person AI-native engineering organisation, Consolidating administrative functions across group companies and improving efficiency through the use of AI |
Items this document does not state (12)
Gross Profit MarginSelling, general and administrative expensesResults for the three months of the current quarterBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookFinancial targetsAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Medical business, M&A contributions increased, as did recurring revenue from the Mighty series and the Insurance Knowledge Platform. In the AI Technology Strategic Business, higher sales at the Philippine subsidiary, cost structure reforms, the strengthening of the AI-driven development framework and the transition of the Japan IBM project to the full development phase contributed to improved profitability.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.